VYNE Therapeutics GAAP EPS of -$2.14 misses by $1.92

Seeking Alpha··Read original
2▲0 ▼1Impact / 5
Summary · why it matters

VYNE Therapeutics reported a second-quarter GAAP loss of $2.14 per share, missing expectations by $1.92. As of June 30, 2026, the company had cash and cash equivalents of $18.7 million. Yarrow expects its cash position, together with $100 million received in July 2026 from the second half of the pre-merger private financings, to fund operations into 2028.

Impact on assets 1

Biotech & Genomic Medicine▼